Skip to content
value.today

Hyperfine, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Medical Devices: $17 M to $46 M, median $32 MPrice to bookPrice to book of Medical Devices: $59 M to $210 M, median $108 M$0 M$57 M$113 M$170 M$226 MMarket value $78 M

Your own DCF model

A full discounted-cash-flow model of Hyperfine, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Medical Devices

Multiples of its companies with a market value at most 60 days old, times Hyperfine, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Hyperfine, Inc.Applied toValue (25th to 75th)Companies
Price to sales1.3× / 2.4× / 3.4×4.1×revenue $14 M$17 M to $46 M37
Price to book1.4× / 2.6× / 5.1×1.9×book equity $41 M$59 M to $210 M37

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Hyperfine, Inc.'s multiples at each month end with a market cap on file, Dec 2022 to Oct 2026, each against its own median.

Price to sales

4.7×

Now below its median of 9.6×, in the bottom quarter of its range; range 4.7× to 42.0× over 6 months.

0×11×21×32×42×2023202420252026Price to sales 5×Median 10×

Price to book

1.9×

Now above its median of 1.8×; range 0.3× to 2.5× over 6 months.

0×1×1×2×3×2023202420252026Price to book 2×Median 2×

as of Oct 23, 2026. Market caps: the dated values on file since 2020. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 23, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$14 M$-36 M$-28 M$1 M$-29 M$-35 MSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$13 M$-41 M$-39 M$0 M$-39 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$11 M$-44 M$-42 M$1 M$-43 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$7 M$-44 M$-72 M$1 M$-73 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$2 M$-65 M$-47 M$3 M$-50 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$0 M$-23 M$-22 M$2 M$-23 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $78 M on Oct 23, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.